Login to Your Account

SABCS 2017

In HER2 breast cancer, expanding choices but still much guesswork

By Anette Breindl
Senior Science Editor

Thursday, December 7, 2017

SAN ANTONIO – Since overexpression of the HER2/Erbb2 receptor was first described as a feature of some breast cancer in 1987, the overexpression has been turned from a negative to a positive predictive factor by the efforts of first academic researchers and then the biopharmaceutical industry.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription